Acute Myocardial Infarction
Conditions
Brief summary
This was a retrospective study using the Taiwan's National Health Insurance Research Database (NHIRD). The study employed two study designs for different purposes as follows: * A cross-sectional analysis was conducted to explore the annual incidence trends. * A longitudinal cohort study was conducted to assess baseline characteristics, treatment patterns, long-term healthcare utilization, and cause-specific mortality among incident AMI patients. In each part, the study was conducted for AMI, and separately for ST-segment elevation and non-ST- segment elevation myocardial infarction (STEMI and NSTEMI)
Interventions
None listed
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Cross-sectional analysis: * Patients aged 20 years and older. * Patients who had been admitted for AMI, defined as primary or first secondary diagnosis of AMI between 2014 and 2020. * The diagnosis of AMI/ STEMI/ NSTEMI was identified by the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes and 10th revision (ICD-10-CM) codes. * Incident cases of AMI hospitalization were defined as no history of AMI-related hospitalization or outpatient visit within 1 year before admission. Longitudinal analysis: Patients aged 20 years and older. * Patients who had been admitted for AMI, defined as primary or first secondary diagnosis of AMI between 2014 and 2017. * The diagnosis of AMI/ STEMI/ NSTEMI was identified by ICD-9-CM codes and ICD-10-CM codes. (The ICD-9-CM code and ICD-10-CM codes were the same as above) * Incident cases of AMI hospitalization were defined as no history of AMI-related hospitalization or outpatient visit within 1 year before admission. * The cohort entry date was defined as the admission date of incident AMI hospitalization, and the index date was defined as the discharge date of incident hospitalization.
Exclusion criteria
None specified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean age of patients | 12 months |
| Number of male patients | 12 months |
| Number of AMI patients with outpatient visits | Up to 3 years |
| Year of patient entry into cohort | 12 months |
| Number of patients with AMI in Taiwan | 12 months |
| Number of patients with STEMI in Taiwan | 12 months |
| Number of patients with NSTEMI in Taiwan | 12 months |
| Number of AMI patients with comorbidities | Up to 3 years |
| Number of patients with treatment for AMI | Up to 3 years |
| Number of STEMI patients with comorbidities | Up to 3 years |
| Number of patients with treatment for STEMI | Up to 3 years |
| Number of NSTEMI patients with comorbidities | Up to 3 years |
| Number of patients with treatment for NSTEMI | Up to 3 years |
| Number of mortalities among AMI patients | Up to 3 years |
| Number of mortalities among STEMI patients | Up to 3 years |
| Number of mortalities among NSTEMI patients | Up to 3 years |
| Number of AMI patients with emergency room visits | Up to 3 years |
| Number of AMI patients with hospitalizations | Up to 3 years |
| Length of hospital stay for AMI patients | Up to 3 years |
| Direct medical costs for AMI patients | Up to 3 years |
| Number of STEMI patients with outpatient visits | Up to 3 years |
| Number of STEMI patients with emergency room visits | Up to 3 years |
| Number of STEMI patients with hospitalizations | Up to 3 years |
| Length of hospital stay for STEMI patients | Up to 3 years |
| Direct medical costs for STEMI patients | Up to 3 years |
| Number of NSTEMI patients with outpatient visits | Up to 3 years |
| Number of NSTEMI patients with emergency room visits | Up to 3 years |
| Number of NSTEMI patients with hospitalizations | Up to 3 years |
| Length of hospital stay for NSTEMI patients | Up to 3 years |
| Direct medical costs for NSTEMI patients | Up to 3 years |
Countries
Taiwan
Outcome results
None listed